AKT1 and medulloblastoma: In line with the enhanced anti-neoplastic effects of the Vandetanib-GDC-combination our findings demonstrate in MYC-amplified medulloblastoma a further reduction in AKT and STAT3 activity respectively in comparison to single drug application.